CytRx's (CYTR) INNO-206 Significantly Inhibits Pancreatic Cancer Growth in Animal Trials
Tweet Send to a Friend
CytRx Corporation (NASDAQ: CYTR) announced that treatment with its cancer drug candidate INNO-206 resulted in a statistically significant reduction in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
